紫花前胡素在动脉粥样硬化中的抗炎作用及其药物安全性评估
收稿日期: 2025-01-03
网络出版日期: 2026-01-30
基金资助
国家自然科学基金项目(82070401)
版权
Anti-inflammatory effects and safety evaluation of decursin in atherosclerosis
Received date: 2025-01-03
Online published: 2026-01-30
Copyright
目的:探讨紫花前胡素在动脉粥样硬化疾病中的抗炎作用及其安全性,并验证其对巨噬细胞炎症反应的调节作用。方法:构建高脂饮食喂养的载脂蛋白E基因敲除(apolipoprotein E deficient, ApoE-/-)雄性小鼠动脉粥样硬化模型,通过氧化型低密度脂蛋白(oxidized low-density lipoprotein, oxLDL)刺激RAW 264.7巨噬细胞以诱导泡沫细胞形成。采用油红O(oil red O, ORO)染色评估主动脉斑块面积减少比例。通过蛋白质印迹检测核因子κB(nuclear factor κB, NF-κB)的磷酸化水平,采用炎症因子阵列分析血清及细胞上清中炎症因子水平,并通过苏木精-伊红(hematoxylin-eosin, HE)染色评估紫花前胡素的全身毒性。结果:紫花前胡素显著减少主动脉斑块面积,在oxLDL刺激的巨噬细胞中,其可抑制NF-κB的过度活化,下调促炎因子[如白介素(interleukin, IL)-2和干扰素(interferon, IFN)-γ]的表达,同时上调抗炎因子(如IL-4和IL-10)的水平。此外,在ApoE-/-小鼠模型中,紫花前胡素同样显著降低了血清中促炎因子水平,提高抗炎因子水平。HE染色结果显示,紫花前胡素未对主要器官造成明显的病理损伤。结论:紫花前胡素通过调控巨噬细胞炎症反应发挥显著的抗炎作用,并减轻动脉粥样硬化病变,安全性较高,有望成为治疗动脉粥样硬化的潜在药物。
陈辉 , 杨玲 , 赵安琪 , 查晴 , 杨克 , 刘艳 . 紫花前胡素在动脉粥样硬化中的抗炎作用及其药物安全性评估[J]. 内科理论与实践, 2026 , 20(06) : 457 -461 . DOI: 10.16138/j.1673-6087.2025.06.05
Objective To investigate the anti-inflammatory effects and safety of decursin in atherosclerosis, and to verify its regulatory role in macrophage inflammatory responses. Methods An atherosclerosis model was established using apolipoprotein E deficient (ApoE-/-) male mice fed a high-fat diet. RAW 264.7 macrophages were stimulated with oxidized low-density lipoprotein (oxLDL) to induce foam cell formation. Oil Red O (ORO) staining was employed to measure the reduction in aortic plaque area. Western blotting was performed to detect the phosphorylation levels of nuclear factor-κB (NF-κB). Inflammatory cytokine levels in serum and cell supernatants were analyzed using inflammatory cytokine arrays. Systemic toxicity of decursin was assessed by hematoxylin-eosin (HE) staining. Results Decursin significantly reduced aortic plaque area and inhibited the excessive activation of NF-κB in oxLDL-stimulated macrophages. It downregulated the expression of pro-inflammatory cytokines [interleukin (IL)-2 and interferon (IFN)-γ] while upregulating anti-inflammatory cytokines (IL-4 and IL-10). Furthermore, in the ApoE-/- mouse model, decursin similarly significantly lowered serum levels of pro-inflammatory cytokines and elevated those of anti-inflammatory cytokines. HE staining results showed that decursin caused no obvious pathological damage to major organs.Conclusions Decursin exerts significant anti-inflammatory effects by regulating macrophage inflammatory responses, alleviates atherosclerotic lesions, and demonstrates a high safety profile, suggesting its potential as a therapeutic agent for atherosclerosis.
Key words: Atherosclerosis; Macrophage; Inflammation; Nuclear factor-κB; Decursin
| [1] | Lusis AJ. Atherosclerosis[J]. Nature, 2000, 407(6801):233-241. |
| [2] | Glass CK, Witztum JL. Atherosclerosis. the road ahead [J]. Cell, 2001, 104(4):503-516. |
| [3] | Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental?[J]. Cardiovasc Res, 2000, 45(3):736-746. |
| [4] | Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis[J]. Trends Cardiovasc Med, 2008, 18(6):228-232. |
| [5] | Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis[J]. Cell, 2011, 145(3):341-355. |
| [6] | Doran AC, Yurdagul A Jr, Tabas I. Efferocytosis in health and disease[J]. Nat Rev Immunol, 2020, 20(4):254-267. |
| [7] | Kasikara C, Doran AC, Cai B, et al. The role of non-resolving inflammation in atherosclerosis[J]. J Clin Invest, 2018, 128(7):2713-2723. |
| [8] | Yurdagul A Jr, Doran AC, Cai B, et al. Mechanisms and consequences of defective efferocytosis in atherosclerosis[J]. Front Cardiovasc Med, 2018, 4: 86. |
| [9] | Bank S, Andersen PS, Burisch J, et al. Polymorphisms in the toll-like receptor and the IL-23/IL-17 pathways were associated with susceptibility to inflammatory bowel disease in a Danish cohort[J]. PLoS One, 2015, 10(12):e0145302. |
| [10] | Jiang C, Lee HJ, Li GX, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer[J]. Cancer Res, 2006, 66(1):453-463. |
| [11] | Kim JH, Jeong JH, Jeon ST, et al. Decursin inhibits induction of inflammatory mediators by blocking nuclear factor-kappaB activation in macrophages[J]. Mol Pharmacol, 2006, 69(6):1783-1790. |
| [12] | Kim WJ, Lee MY, Kim JH, et al. Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kappaB activation[J]. Cancer Lett, 2010, 296(1):35-42. |
| [13] | Islam SU, Lee JH, Shehzad A, et al. Decursinol angelate inhibits LPS-induced macrophage polarization through modulation of the NFκB and MAPK signaling pathways[J]. Molecules, 2018, 23(8):1880. |
| [14] | National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals, 8th edition [EB/OL]. 2011. https://www.ncbi.nlm.nih.gov/books/NBK54050/. |
/
| 〈 |
|
〉 |